A Clinical Study on the Use of Propofol Tenofovir in the Treatment of Chronic Hepatitis B

Zhi-rong ZHAO; Hai-wen LI; Ni-hong LU; Ling SHEN; Xiao-fei LI; Yong-rui YANG

doi:10.12259/j.issn.2095-610X.S20210141

Volume 42 Issue 1

Jan. 2021

Turn off MathJax

Article Contents

Article Navigation > Journal of Kunming Medical University > 2021 > 42(1): 89-93

Zhi-rong ZHAO, Hai-wen LI, Ni-hong LU, Ling SHEN, Xiao-fei LI, Yong-rui YANG. A Clinical Study on the Use of Propofol Tenofovir in the Treatment of Chronic Hepatitis B[J]. Journal of Kunming Medical University, 2021, 42(1): 89-93. doi: 10.12259/j.issn.2095-610X.S20210141

Citation:

Zhi-rong ZHAO, Hai-wen LI, Ni-hong LU, Ling SHEN, Xiao-fei LI, Yong-rui YANG. A Clinical Study on the Use of Propofol Tenofovir in the Treatment of Chronic Hepatitis B[J]. Journal of Kunming Medical University, 2021, 42(1): 89-93. doi: 10.12259/j.issn.2095-610X.S20210141

Citation:

PDF( 629 KB)

A Clinical Study on the Use of Propofol Tenofovir in the Treatment of Chronic Hepatitis B

doi: 10.12259/j.issn.2095-610X.S20210141

1.
School of Public Health，Dali University，Dali Yunnan 671000
2.
Dept.of Hepatology，The 3rd People’s Hospital of Kunming，Kunming Yunnan 650041
3.
School of Public Health，Kunming Medical University，Kunming Yunnan，650500，China

Received Date: 2020-06-01
Available Online: 2021-01-26
Publish Date: 2021-01-26

Abstract

Abstract

Objective to observe the efficacy and safety in the clinic practice of Propofol Tenofavir Fumarate（TAF）as a treatment of Chronic Hepatitis B（CHB） Method A total of 180 Chronic-Hepatitis-B patients who had taken TDF antiviral therapy for 48 to 49 weeks were chosen between January 2018 and February 2020. They were further separated into two groups regarding to the following treatments: one continues TDF treatment while the other replaces with TAF. The comparison was made based on the clinic efficacy and renal safety from such two groups after a 48-week continuous medication. Results TAF group showed a statistical difference significantly better in HBV-DNA inhibition rate, ALT normalization rate, and HBeAg serum conversion with χ² = 10.250, P = 0.001 and χ² = 6.871, P = 0.009, and χ² = 3.881, P = 0.049 respectively. In terms of the safety, TAF group also demonstrates a difference significantly lower in the urinary α1 microglobulin abnormal rate with χ² = 13.703, P = 0.000. On the other hand, there was no significant difference in bloom β2 microglobulin among the groups owning to P values ≥ 0.05. Conclusion With the statistical comparison between TAF and TDF treatments in this clinic study, TAF is observed to have a stronger antiviral effectiveness, fewer side effects such as less induced harm to the renal function, and reduce the risks deriving from the liver cirrhosis and cancer.
- Chronic Hepatitis B,
- TAF,
- Efficacy,
- Safety

FullText(HTML)

References(16)

References

[1]	魏茂武. 健康教育在结核及乙肝传染病中预防控制的应用分析[J].世界最新医学信息文摘,2019,19(67):359-361.
[2]	中华医学会感染病学分会,中华医学会肝病学分会. 慢性乙型肝炎防治指南(2019年版)[J].临床肝胆病杂,2019,35(12):2648-2669.
[3]	任天棋,杨倩倩,马鹤铭,等. TAF治疗慢性乙型肝炎的研究进展[J].肝脏,2019,24(11):1319-1322. doi: 10.3969/j.issn.1008-1704.2019.11.037
[4]	王贵强. 慢性乙型肝炎抗病毒治疗药物选择-2017年版欧洲肝病学会《慢性乙型肝炎病毒感染管理临床实践指南》解读[J].中国病毒病杂志,2017,7(5):330-332.
[5]	Johan W,Soo A,Maria C,et al. Management of hepatitis B virus infection,updated Swedish guidelines.[J]. Infectious Diseases (London,England),2019,54(6):46-69.
[6]	Westin J,Aleman S,Castedal M,et al. Management of hepatitis B virus infection,updated Swedish guidelines[J]. Infect Dis (Lond),2020,52(1):1-22.
[7]	Chan H L Y,Fung S,Seto W K. Tenofovir alafenamide versus tenofovir disoproxil fumarate[J]. Articles,2016,16(1):185-198.
[8]	江宇泳,蔡晧东. 替诺福韦的肾脏-骨骼毒性及其防治[J].药物不良反应杂志,2014,16(3):163-167. doi: 10.3760/cma.j.issn.1008-5734.2014.03.011
[9]	任娜,张婷,程澄,等. 尿β2-微球蛋白作为替诺福韦酯致慢性乙型肝炎患者近端肾小管功能损伤早期预测指标的临床价值[J].中国肝脏病杂志(电子版),2018,10(2):11-17. doi: 10.3969/j.issn.1674-7380.2018.02.003
[10]	张文娟,张静洁,郑志兵. 乙肝治疗新药—替诺福韦艾拉酚胺半富马酸[J].临床药物治疗杂志,2017,15(3):10-13. doi: 10.3969/j.issn.1672-3384.2017.03.003
[11]	王素娜,连建奇,贾战生,等. 富马酸丙酚替诺福韦治疗慢性乙型肝炎的研究现状[J].临床肝胆病杂志,2019,35(8):1828-1833. doi: 10.3969/j.issn.1001-5256.2019.08.040
[12]	丁玲. 尿 α1-MG、尿 β2-MG 在替诺福韦和恩替卡韦短期治疗慢性乙型肝炎早期肾功能变化的意义[D]. 南昌: 南昌大学（硕士学位论文）, 2018.
[13]	王国强,张晟春,赵春平,等. 乙型肝炎患者体液免疫功能、肝纤维化指标及 α1-MG、TGF-β1 水平分析[J].现代生物医学进展,2020,37(4):772-775.
[14]	秦文敬. 乙肝患者尿_2_MG_Alb_IgG测定的临床意义_秦文敬[J].淮海医药,2003,15(5):369-370. doi: 10.3969/j.issn.1008-7044.2003.05.015
[15]	王振华,孙国强,金嘉峻. 探讨血清_2_MG检测在乙肝病毒感染过程中的意义[J].中国高等医学教育,2015,10(5):125-126. doi: 10.3969/j.issn.1002-1701.2015.05.066
[16]	潘锋. 有效抗病毒是降低肝硬化肝癌风险的关键—访中国工程院院士、北京大学医学部庄辉教授[J].中国当代医药,2019,26(2):1-3. doi: 10.3969/j.issn.1674-4721.2019.02.002

Relative Articles(20)

Relative Articles

[1]	Keyan WANG, Bingting LIN, Xiaolin WENG, Bin HUANG, Lie WANG. Effectiveness and Safety Analysis of Cyclopol Combined with Remifentanil in Anesthesia for Endoscopic Gastric Cancer Radical Surgery. Journal of Kunming Medical University, 2024, 45(6): 154-160. doi: 10.12259/j.issn.2095-610X.S20240621
[2]	Liyuan YUN, Junfeng WANG, Ning GUO, Ruimei DING, Haipeng LI, Xueping ZHANG. Analysis of the Efficacy and Safety of GM1 Injection Combined with Batroxobin in the Treatment of Sudden Deafness Patients. Journal of Kunming Medical University, 2024, 45(6): 140-144. doi: 10.12259/j.issn.2095-610X.S20240619
[3]	Chunyan CHEN, Zimian FAN. Correlation Analysis of Peripheral Blood SAA/CRP and NLR Levels with HBV-DNA Lload and Degree of Disease in CHB Patients. Journal of Kunming Medical University, 2024, 45(5): 144-150. doi: 10.12259/j.issn.2095-610X.S20240522
[4]	Fen TENG, Bo TIAN, Chongxi LI, Yongmei JIN, Haiyun CHEN, Jun LIU. Real-World Clinical Efficacy and Safety of Bictegravir/Emtricitabine/Tenofovir Alafenamide （BIC/FTC/TAF） Single-Tablet Regimen. Journal of Kunming Medical University, 2024, 45(4): 74-80. doi: 10.12259/j.issn.2095-610X.S20240411
[5]	Xiaohua LU, Hongxin YUAN. The Analysis of the Correlation between BTLA，CTLA-4 Gene Polymorphisms and the Efficacy and Prognosis of TACE Combined Targeted Therapy for Liver Cancer. Journal of Kunming Medical University, 2023, 44(9): 126-135. doi: 10.12259/j.issn.2095-610X.S20230927
[6]	Jianmei LI, Yanling JIN. Efficacy and Safety of Bortezomib，Lenalidomide Combined with Dexamethasone in the Treatment of Multiple Myeloma. Journal of Kunming Medical University, 2023, 44(6): 120-125. doi: 10.12259/j.issn.2095-610X.S20230610
[7]	Xing LIU, Chunhong YU, Weixian LI, Bing OUYANG, Lingjun SHEN. A Randomized Controlled Study on the Treatment of Multidrugresistant Tuberculosis with a Regimen Containing Bedaquiline Fumarate Tablets. Journal of Kunming Medical University, 2023, 44(12): 150-158. doi: 10.12259/j.issn.2095-610X.S20231224
[8]	Zhi-rong ZHAO, Hai-wen LI, Xiao-fei LI, Ni-hong LU, Yong-rui YANG. Efficacy and Safety of Sofosbuvir/Vipatavir Combined with Ribavirin in Treatment of Genotype 3 Patients with Chronic Hepatitis C. Journal of Kunming Medical University, 2021, 42(3): 98-103. doi: 10.12259/j.issn.2095-610X.S20210325
[9]	Jin-jiang YANG, Liu-jiang LI, Shi-jun SHEN, Zhao-xiang LI, Yong YANG, Guo-jian LI. Clinical Trial of Rivaroxaban after Implantation of Stent for Femoral Popliteal Atherosclerosis Occlusion. Journal of Kunming Medical University, 2020, 41(11): 83-87. doi: 10.12259/j.issn.2095-610X.S20201122
[10]	Xie Wei , Zhao Chuan , Wang Rong , Wang Wen Ping , Tu Hong . . Journal of Kunming Medical University, 2020, 41(02): 82-86.
[11]	Hu Wei Hua . The Observation of Clinical Effect of Using Ambroxol in the Treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease. Journal of Kunming Medical University,
[12]	Chang Song Jie . The Clinical Efficacy and Safety of Decreasing Blood Uric Acid by Benzene Bromine Malone in Treatment of Hyperuricemia with Elderly Hypertension and Diabetes Mellitus. Journal of Kunming Medical University,
[13]	Luo Yong Li . Clinical Assessment on the Safety of Cardiac Rehabilitation for the Elderly Patients with Chronic Heart Failure. Journal of Kunming Medical University,
[14]	Pan Zi Peng . Analysis and Safety Evaluation of the Clinical Efficacy of Laparoscopic Appendectomy for Acute Appendicitis. Journal of Kunming Medical University,
[15]	Ning Lin . . Journal of Kunming Medical University,
[16]	Zeng Hai Ping . . Journal of Kunming Medical University,
[17]	Wang Ji Cai . . Journal of Kunming Medical University,
[18]	Yang Yong Rui . . Journal of Kunming Medical University,
[19]	Guo Xian Li . . Journal of Kunming Medical University,
[20]	Wang Ji Cai . . Journal of Kunming Medical University,